"Painchek a great buying opportunity" says CEO, Phillip Daffas.

If you are looking for examples of companies that reflect the strange market valuations that are around today, just ask Phillip Daffas, CEO of Painchek.

Paincheck (ASX:PCK) is currently trading at about the same price as it was, when it had no customers. Yet, at the time of writing, it has annual recurring revenue of more than $100k and, according to Daffas, a strong sales pipeline,.

Painchek is a mobile medical application that uses facial recognition software to facilitate and improve pain assessment in patients that are unable to communicate. To learn more about Painchek's product you can watch the corporate video, or skip straight to my interview with their CEO.

We do not recommend or advise to buy or sell shares in Painchek. The InsideMarket Private Fund does not own shares in Painchek at this time, nor have we received any payment from the company for this coverage. Disruptive technology stocks should be considered very speculative, high-risk, and very volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.